Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Ruijin Hospital is the lead sponsor of 281 current clinical trials in our China register. 180 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Rituximab, Decitabine and Orelabrutinib. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting18064%
Not yet open6322%
Active, closed2710%
By invitation114%

Trials by phase

Observational8932%
Not applicable6724%
Phase 26623%
Phase 1166%
Phase 3155%
Phase EARLY_PHASE1114%
Phase 1/2104%
Phase 452%
Phase 2/321%

Clinical trials sponsored by Ruijin Hospital

281 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy NCT06589089 · Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	2024-10	China
Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension NCT06829134 · Hypertension, Retroperitoneal Disease	Not applicable	Recruiting	2025-03	China
Directional PSA Versus STN DBS for TD-PD NCT07700862 · ClinicalTrials.gov ↗ · Parkinsons Disease (PD)	Not applicable	Recruiting	2026-07	China
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. NCT06601010 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Observational	Recruiting	2024-09	China
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer NCT04517266 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2021-03	China
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases NCT06747156 · ClinicalTrials.gov ↗ · Autoimmune Diseases Drug: ABO2203	Phase EARLY_PHASE1	Recruiting	2024-12	China
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL NCT07380984 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma Drugs: Chidamide, Golidocitinib	Phase 2	Recruiting	2026-03	China
Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection NCT06821451 · ClinicalTrials.gov ↗ · Lung Nodules	Not applicable	Recruiting	2025-02	China
Spinal Cord Stimulation for Parkinsonism NCT05171205 · ClinicalTrials.gov ↗ · Parkinsonism	Not applicable	Recruiting	2021-05	China
Clinical Applications of FAPI PET in Solid Tumors NCT07776899 · ClinicalTrials.gov ↗ · Solid Tumor	Not applicable	Recruiting	2026-07	China
PSA Versus STN DBS for DT NCT06752434 · ClinicalTrials.gov ↗ · Dystonic Tremor	Not applicable	Recruiting	2024-12	China
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer NCT05576480 · ClinicalTrials.gov ↗ · Rectal Cancer, Locally Advanced Drugs: Capeox, Penpulimab	Phase 2	Recruiting	2023-02	China
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer NCT07080021 · ClinicalTrials.gov ↗ · Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma	Observational	Recruiting	2025-05	China
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study NCT06998706 · ClinicalTrials.gov ↗ · Interstitial Lung Disease (ILD) Drug: REGEND001 Autologous Basal Layer Stem Cell	Phase 1	Recruiting	2025-06	China
Risk Evaluation and Management in Heart Failure NCT02998788 · ClinicalTrials.gov ↗ · Heart Failure, Risk Factor, Cardiovascular	Observational	Recruiting	2016-06	China
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) NCT06534463 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma	Observational	Recruiting	2024-08	China
Non-Invasive Neuromodulation for Essential Tremor: Long-Term Safety and Effectiveness Study NCT07774598 · ClinicalTrials.gov ↗ · Essential Tremor	Not applicable	Recruiting	2025-12	China
Shanghai Clinical Cohort - Parkinson's Disease (Reserve) NCT07353463 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD), Multiple System Atrophy	Observational	Recruiting	2025-04	China
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy NCT05552846 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Not applicable	Recruiting	2021-01	China
Retrograde Ascending Dissection: Intraluminal Aortic Therapy NCT07405242 · ClinicalTrials.gov ↗ · Ascending Aortic Dissection	Not applicable	Recruiting	2026-01	China
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment NCT06496308 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL) Drugs: Bendamustine, Orelabrutinib, Rituximab	Phase 3	Recruiting	2024-07	China
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study NCT06987214 · ClinicalTrials.gov ↗ · Bronchiectasis Adult Drug: REGEND001 Autologous Basal Layer Stem Cell	Phase 1	Recruiting	2025-06	China
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV NCT06793787 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS)	Observational	Recruiting	2024-07	China
Safety and Efficacy of IMPT or IMRT for Breast Cancer NCT06826885 · ClinicalTrials.gov ↗ · Breast Cancer, Proton Therapy, Intensity Modulated Radiation Therapy	Observational	Recruiting	2024-12	China
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165 · ClinicalTrials.gov ↗ · Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy	Phase 2	Recruiting	2025-09	China
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy NCT06746194 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2024-12	China
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma NCT04072042 · ClinicalTrials.gov ↗ · Sarcoma Drug: Apatinib	Phase 2	Recruiting	2019-10	China
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC) NCT05556603 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	2022-12	China
Adjuvant Pancreatic Therapy Guided by MRD NCT06966440 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Resectable	Not applicable	Recruiting	2025-06	China
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients NCT05277688 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	2022-03	China
TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System NCT06818084 · ClinicalTrials.gov ↗ · AORTIC VALVE DISEASES, Aortic Regurgitation, Transcatheter Aortic Valve Replacement (TAVR)	Phase 4	Recruiting	2025-04	China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A. NCT07229547 · ClinicalTrials.gov ↗ · Influenza	Phase 3	Recruiting	2025-11	China
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection NCT06541327 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Observational	Recruiting	2024-05	China
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas NCT06644287 · ClinicalTrials.gov ↗ · Advanced Soft Tissue Sarcomas	Observational	Recruiting	2024-10	China
Prospective Management of Plaque Instability With Statins and Extra Folic Acid NCT07680595 · ClinicalTrials.gov ↗ · Carotid Atherosclerotic Plaque Drug: Atorvastatin	Phase 1/2	Recruiting	2026-03	China
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia NCT06534658 · ClinicalTrials.gov ↗ · Alzheimer Disease, Image	Observational	Recruiting	2020-07	China
Exploration of Circular RNA in B-cell Hematologic Malignancies NCT07774572 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell Refractory	Phase 1	Recruiting	2026-05	China
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases) NCT06601075 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Observational	Recruiting	2025-02	China
Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer NCT04527861 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colon Cancer, Rectal Cancer	Not applicable	Recruiting	2021-04	China
Risk Factors and Outcomes in Coronary Chronic Total Occlusion NCT06137521 · ClinicalTrials.gov ↗ · Chronic Total Occlusion, Coronary Artery Disease	Observational	Recruiting	2010-01	China
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases NCT06567353 · ClinicalTrials.gov ↗ · Breast Neoplasms, Liver Neoplasms, Metastasis	Not applicable	Recruiting	2024-12	China
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma NCT06136351 · ClinicalTrials.gov ↗ · Lymphoma, Mantle-Cell Drugs: Rituximab, Zanubrutinib	Phase 2	Recruiting	2023-11	China
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment NCT07199296 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL) Drugs: Orelabrutinib, Rituximab	Phase 2	Recruiting	2025-07	China
a Feasibility Study of iHD-SRT for BM NCT06231186 · ClinicalTrials.gov ↗ · Brain Metastases, Adult, Stereotactic Radiotherapy	Not applicable	Recruiting	2024-03	China
Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients NCT06404697 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2024-05	China
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) NCT06074692 · ClinicalTrials.gov ↗ · Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone	Phase 2	Recruiting	2023-06	China
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors NCT07004647 · ClinicalTrials.gov ↗ · Peritoneal Tumor	Not applicable	Recruiting	2025-03	China
Prospective Exploratory Study on rTMS for Migraine Under the Guidance of MEG NCT06796725 · ClinicalTrials.gov ↗ · Migraine Disorders, Brain, rTMS Stimulation	Not applicable	Recruiting	2025-02	China
Pilot Trial of Colchicine for Graft Failure in CABG NCT06802926 · ClinicalTrials.gov ↗ · CABG, Graft Failure, Colchicine Drug: Colchicine	Phase 4	Recruiting	2025-12	China
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment NCT07067385 · ClinicalTrials.gov ↗ · Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors	Phase 1	Recruiting	2025-07	China
A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease NCT06992661 · ClinicalTrials.gov ↗ · Interstitial Lung Disease (ILD), Healthy Volunteers	Phase 1	Recruiting	2025-05	China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses NCT06693362 · ClinicalTrials.gov ↗ · Severe Viral Pneumonia(Not Include COVID-19)	Phase 1	Recruiting	2025-01	China
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer NCT06368141 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 2	Recruiting	2024-05	China
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma NCT06494371 · ClinicalTrials.gov ↗ · Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma	Phase 1	Recruiting	2024-07	China
A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai NCT05387304 · ClinicalTrials.gov ↗ · COVID-19	Observational	Recruiting	2022-03	China
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma NCT06122493 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2022-11	China
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma NCT07028086 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myeloid Sarcoma	Phase 2	Recruiting	2025-06	China
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: IBI343, Oxaliplatin, Sintilimab	Phase 1/2	Recruiting	2025-06	China
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease NCT07272499 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL) Drugs: Lisaftoclax, Orelabrutinib, Rituximab	Phase 2	Recruiting	2025-09	China
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL NCT06779435 · ClinicalTrials.gov ↗ · DLBCL	Observational	Recruiting	2025-01	China
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma NCT05662540 · ClinicalTrials.gov ↗ · NK/T-cell Lymphoma	Not applicable	Recruiting	2023-05	China
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7% NCT07115992 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostate Adenoma	Not applicable	Recruiting	2025-07	China
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis NCT07384234 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma Drugs: Capecitabine, Oxaliplatin, Paclitaxel	Phase 2	Recruiting	2026-04	China
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 NCT06718244 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 2	Recruiting	2024-12	China
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Observational	Recruiting	2023-06	China
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma NCT07795528 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage I Colon Cancer, Stage II Colon Cancer	Observational	Recruiting	2026-08	China
Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation NCT07498855 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2025-10	China
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3). NCT06339060 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 3	Recruiting	2024-05	China
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer. NCT06608160 · ClinicalTrials.gov ↗ · PET / CT, Lung Carcinoma, Immunotherapy	Observational	Recruiting	2024-06	China
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer NCT05140746 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Recruiting	2020-09	China
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT NCT07511127 · ClinicalTrials.gov ↗ · Hematologic Malignancy Drug: Maribavir	Phase 3	Recruiting	2026-02	China
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy NCT07306286 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Locally Advanced	Phase 2	Recruiting	2025-12	China
A Multimodal Prospective Cohort Study of Parkinsonism NCT07553845 · ClinicalTrials.gov ↗ · Parkinsonism, REM Sleep Behavior Disorder	Observational	Recruiting	2024-05	China
Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer NCT05976412 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2023-07	China
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	2024-04	China
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer NCT06623487 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, PET / CT, Neoadjuvant Immunotherapy	Observational	Recruiting	2024-07	China
(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis NCT07151521 · ClinicalTrials.gov ↗ · ANCA-associated Vasculitis	Observational	Recruiting	2025-09	China
CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial NCT07769008 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography	Not applicable	Recruiting	2026-08	China
Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma Drugs: Chidamide, CHOP, Duvelisib	Phase 1/2	Recruiting	2023-02	China
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma NCT05348213 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma Drugs: Chidamide, Decitabine, Pomalidomide	Phase 2	Recruiting	2022-05	China
Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment NCT03829553 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	2019-02	China
Predicting DBS Outcomes in Dystonia Using Wearable Gait Sensors NCT07323602 · ClinicalTrials.gov ↗ · Dystonia	Observational	Recruiting	2025-08	China
Comparison of Drainage Methods in Minimally Invasive Esophagectomy (DEMURE） NCT07004634 · ClinicalTrials.gov ↗ · Esophageal Cancer, Drainage/Methods, Postoperative Pain	Not applicable	Recruiting	2025-04	China
Efficacy and Safety of tACS for Depression: a Multicenter RCT Study NCT06891326 · ClinicalTrials.gov ↗ · Depression Disorders	Not applicable	Recruiting	2024-10	China
PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques NCT06794684 · ClinicalTrials.gov ↗ · Coronary Arterial Disease (CAD), Coronary Arteriosclerosis	Observational	Recruiting	2016-01	China
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma NCT06522555 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	2024-07	China
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer NCT05557552 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III	Not applicable	Recruiting	2022-09	China
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study NCT07556640 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	2026-04	China
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA) NCT04858724 · ClinicalTrials.gov ↗ · IgA Nephropathy	Observational	Recruiting	2020-12	China
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma NCT06795113 · ClinicalTrials.gov ↗ · Lymphoma	Observational	Recruiting	2013-06	China
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS NCT07607418 · ClinicalTrials.gov ↗ · AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) Drug: Ivosidenib	Phase 2	Recruiting	2026-05	China
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer NCT07026149 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	2025-06	China
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 · ClinicalTrials.gov ↗ · AML, MDS Drugs: Decitabine, Venetoclax	Phase 2/3	Recruiting	2025-06	China
Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai NCT06641856 · ClinicalTrials.gov ↗ · Health Personnel	Observational	Recruiting	2024-09	China
A Fast, Quiet, Artificial Intelligence-based PET/MR Solution for Paediatric Diseases NCT06709690 · ClinicalTrials.gov ↗ · Paediatric Patients	Observational	Recruiting	2024-10	China
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC NCT07085169 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102 Drugs: Bevacizumab, Trifluridine/Tipiracil	Phase 2	Recruiting	2025-08	China
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy NCT07628738 · ClinicalTrials.gov ↗ · Lymphoma (Non-Hodgkin's Lymphoma)	Phase 2	Recruiting	2026-07	China
Shanghai At Risk for Alzheimer's Disease: a Cohort Study NCT05597410 · ClinicalTrials.gov ↗ · Alzheimer Disease, Dementia, Neurodegenerative Diseases	Observational	Recruiting	2022-03	China
BCI With 40Hz Stimulation in Alzheimer's Disease NCT07618481 · ClinicalTrials.gov ↗ · Alzheimer Dementia (AD)	Not applicable	Recruiting	2026-05	China
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease NCT07191444 · ClinicalTrials.gov ↗ · Still's Disease, Adult-Onset Drugs: Anakinra, Firsekibart	Observational	Recruiting	2025-09	China

Showing the 100 most recently updated of 281 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Ruijin Hospital trials

85 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 45 more in the trial list above.

Conditions in Ruijin Hospital trials

336 conditions

Breast Cancer10 Pancreatic Cancer7 Heart Failure5 Alzheimer Disease5 Gastric Cancer5 Diffuse Large B Cell Lymphoma4 Rectal Cancer4 Dementia4 Mantle Cell Lymphoma (MCL)4 Coronary Artery Disease4 Hematologic Malignancy4 Acute Myeloid Leukemia4Parkinsonism3Multiple System Atrophy3Neurodegenerative Diseases3Cognitive Impairment3Large B-Cell Lymphoma (LBCL)3MDS3 AML, Adult3 Large B-cell Lymphoma3 DLBCL3Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma3Diffuse Large B-Cell Lymphoma3T-NK Cell Lymphoma2

By trial register

Register	Trials	Recruiting
Clinical trials in China	281	180

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Ruijin Hospital trials

How many clinical trials does Ruijin Hospital sponsor?

Ruijin Hospital is the lead sponsor of 281 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ruijin Hospital trials recruiting?

Yes. 180 of its 281 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ruijin Hospital testing?

Its current trials name 85 drugs and biologicals as interventions. The most frequent are Rituximab (9), Decitabine (7), Orelabrutinib (7), Zanubrutinib (7) and Cyclophosphamide (6). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Ruijin Hospital clinical trials